If you are interested in participating in a clinical trial at Aurora
Health Care, learn more
on our Web site.
Randomized clinical trial testing of a new drug for non-constipating
irritable bowel syndrome. Nimish Vakil, M.D., principal investigator.
Randomized clinical trail testing of a new drug for gastroesophageal
research disease (GERD). Nimish Vakil, M.D., Peter Johnson, M.D.,
principal investigators.
Study of a device to close a patient foramen ovale (hole in the
heart). Randomized to medical management for patients who have had a
stroke or a mini-stroke. Tanvir Bajwa, M.D., principal investigator.
Randomized clinical trail testing of a new drug for pulmonary
hypertension. Dianne Zwicke, M.D., principal investigator.
Study to evaluate a new test that measures YKL-40 to see if the
amount of YKL-40 in the blood can help monitor ovarian cancer. Peter
Johnson, M.D., principal investigator.
Study to compare the effectiveness, safety, and the impact on
health-related quality of life of cisplatin and paclitaxel, cisplantin
and paclitaxel plus bevacizumab, paclitaxel and topotecan, as well as
paclitaxel and topotecan plus bevacizumab for patients with cancer of
the cervix that is not curable by surgery or radiation therapy. Peter
Johnson, M.D., principal investigator
Study to compare the effects of radiation therapy to the pelvis with
vaginal radiation therapy combined with three cycles of the chemotherapy
drugs paclitaxel and carboplatin to find out which works better in
reducing the chance that of recurrence of cancer for patients with
high-risk early stage endometrial cancer that appears to be confined to
the uterus. Peter Johnson, M.D., principal investigator.
A minimal risk “observational” study that will enroll 720 lung
cancer patients, including 120 female never-smokers (less than 100
cigarettes lifetime), 120 male never-smokers, 240 female smokers, and
240 male smokers. Mitchell Pincus, M.D., principal investigator.
Testing the use of artificial iris lens implants to treat congenital
anomalies and eyes damaged by surgical or severe trauma. The Model 311
Artificial Iris Lens was designed to reduce, minimize or eliminate
visual disturbances caused by the lack of adequate iris tissue. Kevin Weinker, M.D., principal investigator.
